News · Supplements
Zinc cut infections by 38% in young children with sickle cell disease in a Ugandan trial
Zinc is one of the most-bought supplements in the world and one of the least-tested against hard outcomes. A JAMA trial randomized 100 Ugandan children under five and counted every infection for six months.
- Zinc cut infections by nearly 40% in young children with sickle cell disease.
- 80 infections in the zinc group against 124 on placebo, over six months.
- Every child stayed in the trial to the end, which almost never happens.
- These children have a disease that depletes zinc; this is not a case for zinc generally.
- One hospital and 100 children: a strong signal, and not yet a policy.
Zinc is bought by tens of millions of people every winter on the strength of some short trials in the common cold. It is very rarely tested against something that lands people in hospital.
Writing in JAMA, researchers did exactly that, in the population where the stakes are highest. Despite existing prevention strategies, infections remain a major cause of morbidity and mortality in children in Africa with sickle cell anemia, and infection is what kills most of the children with this disease who die young.
There were 80 all-cause infections in the zinc group and 124 in the placebo group, over six months.
Why zinc, in these children
Sickle cell disease is a group of inherited red blood cell disorders in which hemoglobin forms into stiff rods within the red blood cells, turning discs into crescents.
Two consequences follow. The sickle cells usually only last 10 to 20 days, instead of the normal 90 to 120 days, so the body is constantly rebuilding red cells and losing the minerals that go into them. And the spleen, which filters bacteria out of the blood, is damaged early by the same blocked vessels, leaving children vulnerable to exactly the infections that healthy immune systems handle quietly.
Zinc sits at the intersection. It is required for the function of several immune cell types, and it is depleted faster in people with high red cell turnover. That is a specific hypothesis in a specific population, which is what makes this trial more informative than another cold study.
What the trial did
Among 118 children screened for eligibility, 100 were randomly assigned to receive zinc supplementation or placebo, 20 milligrams of zinc sulfate a day for six months, at a regional referral hospital in Jinja.
All participants initiated or continued receiving hydroxyurea after enrollment, which matters: hydroxyurea is the standard disease-modifying treatment and it reduces complications on its own. This trial asked whether zinc adds anything on top of proper care, not whether it substitutes for it.
The follow-up is the detail worth pausing on. During the 6-month follow-up, there was complete ascertainment for all participants and no loss to follow-up. Nobody dropped out. In a trial of small children over half a year, that is close to unheard of.
The size of the effect
There was a significantly lower infection rate in the zinc group than the placebo group, roughly 38% fewer.
In absolute terms, 305.7 infections per 100 person-years against 480.7, a difference of 176 per 100 person-years. For a family, that is a difference measured in fevers, clinic visits and nights that turn into admissions.
The interval runs from 0.45 to 0.86, which excludes no effect comfortably but leaves the true size loosely pinned. One hundred children and 204 infections is not a large trial; the reason it can detect anything is that infections in this group are frequent enough to count quickly.
What this is not
It is not a case for zinc as a general immune supplement, and that is the misreading this finding invites.
Dietary supplements are vitamins, minerals, herbs, and many other products, and supplements do not have to go through the testing that drugs do. Zinc is among the most heavily marketed of them, usually to healthy adults on the vague premise of immune support.
Nothing in this trial supports that. These were children under five with an inherited disease that depletes zinc, in a country with a high burden of malaria and bacterial infection, on top of standard treatment. The plausible reading is that correcting a deficiency in people who have one produces a benefit, which says very little about supplementing people who do not.
The wider point
The authors are careful about scope: multisite clinical trials are needed to validate these findings and to assess effectiveness in older children.
What makes the result worth reporting anyway is where it sits. Sickle cell disease affects millions of children, overwhelmingly in sub-Saharan Africa, and receives a fraction of the research funding directed at conditions of similar burden in wealthier countries. Twenty milligrams of zinc sulfate costs almost nothing.
An intervention that cheap, in a disease that neglected, with a 38% reduction in infections and complete follow-up, is the sort of finding that deserves the multisite trial the authors are asking for.
People also ask
What did the trial find?
There were 80 all-cause infections in the zinc group and 124 in the placebo group, a significantly lower infection rate (305.7 per 100 person-years vs 480.7; rate difference -176.0; incidence rate ratio after adjustment for baseline age, sex, and hydroxyurea use, 0.62, 95% CI 0.45-0.86).
Why zinc, and why these children?
Zinc is needed for immune cell function and people with sickle cell disease lose more of it, partly through the rapid turnover of red blood cells. Despite existing prevention strategies, infections remain a major cause of morbidity and mortality in children in Africa with sickle cell anemia.
What is sickle cell disease?
A group of inherited red blood cell disorders in which hemoglobin forms stiff rods, changing cells from discs into crescents. The sickle cells burst early, causing anemia, and can stick to vessel walls and block blood flow, which produces attacks of sudden severe pain.
How well was the trial run?
Unusually well for its size. It was double-blind and placebo-controlled, and during the 6-month follow-up there was complete ascertainment for all participants and no loss to follow-up, which almost never happens.
Was it safe?
No adverse events requiring discontinuation of the study intervention were observed in either group. Six months is short for detecting slower harms, and zinc taken long-term can interfere with copper absorption, which this trial was not designed to see.
Does this apply to healthy adults buying zinc?
No. These were children under five, with an inherited disease that depletes zinc, in a setting with a high infection burden. Nothing here supports zinc for an otherwise healthy person's immune system.
What happens next?
The authors say multisite clinical trials are needed to validate these findings and to assess effectiveness in older children. One hundred children at one hospital is a strong signal and not a policy. This is general information rather than medical advice.